Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Ph 1b portion of Ph 1b/2 lanraplenib study in patients with R/R FLT3-mutated AML completed

January 10, 2024

First Patient Dosed in Trial Evaluating Efti and BAVENCIO in Metastatic Urothelial Cancer

January 10, 2024

First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers

January 10, 2024

Ph 3 INTerpath-002 Study of V940 (mRNA-4157) – KEYTRUDA combination for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC

December 19, 2023

First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer

December 19, 2023

First Patients Enrolled in 60 mg Dose Cohort in Ph 2a Trial of SLS009 in AML

December 19, 2023

Enrollment of Ph 2/3 Trial of Fruquintinib + Sintilimab for Advanced RCC in China completed

December 19, 2023

CB-010 Ph 3 Trial Initiation Expected by YE 2024

December 19, 2023

Confirmatory Ph 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer initiated

December 19, 2023

Patient Enrollment in Ph 2 Pancreatic Cancer Trial of CM24 Completed

December 19, 2023

First Patient Enrolled in Ph 2 Study of BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu

December 11, 2023

STELLAR-305 Ph 2/3 Pivotal Trial of Zanzalintinib + Keytruda in Patients with 1L Recurrent or Metastatic Head and Neck Cancer announced

December 11, 2023

Registrational Ph 3 CLARIFY trial in prostate cancer commences

December 11, 2023

Patient Enrollment of Ph 3 ECLIPSE Trial Ahead of Schedule Completed

December 11, 2023

First Patient Dosed in Ph 1a Trial of QN-302 in Advanced or Metastatic Solid Tumors

December 11, 2023

Patient Enrollment in Global Ph 3 Trial of Buparlisib (AN2025) + Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC completed

December 11, 2023

Partial Clinical Hold For NX-2127 Ph 1 Trial Announced

November 7, 2023

Completion of the Safety Lead-In and Opening of Ph 2 of the AIPAC-003 Ph 2/3 Trial in Metastatic Breast Cancer Announced

November 7, 2023

First Patient Dosed in the Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Patients

October 25, 2023

First Patient Cohort dosed in Ovarian Cancer CER-T Clinical Trial

October 25, 2023

First Patient Dosed in Ph 1/2 Study of BDC-3042 in Patients with Advanced Cancers

October 25, 2023

First Patients Dosed in First-in-Human Ph 1 Study of FX-909 in Advanced Solid Tumors, Including Urothelial Cancer

October 25, 2023

Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023

October 18, 2023

Clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab to be discontinued

October 18, 2023

First Patient Dosed in Ph 1b/2 Trial of SLS009 (GFH009) in R/R PTCL

October 18, 2023
Page1 … Page13 Page14 Page15 Page16 Page17 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.